Treatment of multiple myeloma
AssigneeNational University of Ireland, Galway
InventorsMichael O'DWYER, John DALY, Sarkar SUBHASHIS
Life of this patent
Estimating the term…
Abstract
Provided is an effective amount of a desialylation agent and an effective amount of an anti CD38 antibody for use in the treatment of multiple myeloma. This results in potentiated primary NK cell activity against the multiple myeloma cell. Also envisaged is a method of treating multiple myeloma in a subject in need thereof.
Claims27
An effective amount of a desialylation agent and an effective amount of a CD38 targeting agent, for use in the treatment of a CD38 positive disease.
The desialylation agent and CD38 targeting agent for use any one of the preceding claims, further comprising a modified NK cell.
The desialylation agent and CD38 targeting agent for use of any one of the preceding claims, further comprising an effective amount of an agent that increases the expression of CD38 on the surface of a cell.
The desialylation agent and CD38 targeting agent for use of any one of the preceding claims, wherein the desialylation agent is selected from the group comprising a sialidase enzyme and sialytransferase inhibitor (SIA).
The desialylation agent and CD38 targeting agent for use of any one of the preceding claims, in which the CD38 targeting agent is selected from the group comprising a peptide, a small molecule, a peptide mimic, an antagonist, an antibody and an immune cell.
The desialylation agent and CD38 targeting agent for use of any one of the preceding claims, wherein the desialylation agent and the CD38 binding agent are in the form of a conjugate.
An effective amount of a desialylation agent, an effective amount of an agent that increases the expression of CD38 on the surface of a cell, and an effective amount of a CD38 targeting agent, for use in the treatment of a CD38 positive disease.
An effective amount of a desialylation agent, an effective amount of a modified NK cell and an effective amount of a CD38 targeting agent for use in the treatment of a CD38 positive disease.
An effective amount of a desialylation agent, an effective amount of a modified NK cell, an effective amount of an agent that increases the expression of CD38 on the surface of a multiple myeloma cell and an effective amount of a CD38 binding agent, for use in the treatment of a CD38 positive disease.
A conjugate comprising a desialylation agent and a CD38 targeting agent.
A method for the treatment of a CD38 positive disease in a subject, said method comprising administration of a desialylation agent and a CD38 targeting agent, to said subject.
Dependencies are inferred from the claim text.